Analysts at Maxim Group initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) in a research report issued to clients and investors on Friday, AnalystRatings.com reports. The firm set a “buy” rating and a $4.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 64.61% from the stock’s previous close.
A number of other research firms also recently weighed in on NAVB. HC Wainwright upped their price target on shares of Navidea Biopharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday. Zacks Investment Research downgraded shares of Navidea Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 19th.
NYSEAMERICAN NAVB opened at $2.43 on Friday. Navidea Biopharmaceuticals has a 1-year low of $0.49 and a 1-year high of $3.50.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
See Also: Earnings Per Share (EPS)
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.